Hepatocellular carcinoma (HCC) is the third main cause of cancer-related death. Cyclin-dependent kinases (CDKs) and their cyclin partners regulate the cell cycle. Since inhibition of CDKs gives some guiding ideas for cancer studies, we aimed to determine the possible effects of R547, a cyclin kinase 1-2-4 inhibitor, on proliferation and apoptotic mechanisms of Hep G2 cells (human) and H-4- II-E cells derived from rat HCC. We determined in vitro survival rates with MTT assay, apoptosis with flow cytometry, morphological changes with confocal microscopy, and ultrastructural changes by transmission electron microscopy. Cisplatin was used as a positive control. After 24 h of culture with 0.1, 1, 10, 50, and 100 ?M doses of R547, the corresponding percentages of live Hep G2 cells were 101%, 94%, 93%, 89%, and 79% (P < 0.001), respectively. However, with the same R547 doses the live Hep G2 cell percentages were 92%, 101%, 53.6% (P
R547, hepatocellular carcinoma, Hep G2, H-4-II-E, apoptosis, flow cytometry, microscopy
HACIOĞLU, BETÜL; KUŞ, GÖKHAN; KUTLU, HATİCE MEHTAP; and KABADERE, SELDA
"The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death,"
Turkish Journal of Biology: Vol. 44:
1, Article 3.
Available at: https://journals.tubitak.gov.tr/biology/vol44/iss1/3